An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.
about
Clinical use and applications of histone deacetylase inhibitors in multiple myelomaHDAC inhibitors and immunotherapy; a double edged sword?Fas Versatile Signaling and Beyond: Pivotal Role of Tyrosine Phosphorylation in Context-Dependent Signaling and DiseasesThe Impact of Chemotherapy, Radiation and Epigenetic Modifiers in Cancer Cell Expression of Immune Inhibitory and Stimulatory Molecules and Anti-Tumor EfficacyA phase 1 dose-escalation study of the oral histone deacetylase inhibitor abexinostat in combination with standard hypofractionated radiotherapy in advanced solid tumors.Synthetic induction of immunogenic cell death by genetic stimulation of endoplasmic reticulum stress.BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1Augmenting antitumor immune responses with epigenetic modifying agents.Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells.Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Quantitative Analysis of Global Proteome and Lysine Acetylome Reveal the Differential Impacts of VPA and SAHA on HL60 CellsThe SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostaThe modulation of Dicer regulates tumor immunogenicity in melanoma.Convection enhanced delivery of panobinostat (LBH589)-loaded pluronic nano-micelles prolongs survival in the F98 rat glioma model.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.The anticancer effects of HDAC inhibitors require the immune system.Emerging approaches for histone deacetylase inhibitor drug discovery.Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.Combining Epigenetic and Immunotherapy to Combat Cancer.How do tumor cells respond to HDAC inhibition?In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.Immunogenic Apoptotic Cell Death and Anticancer Immunity.HDACs and HDAC Inhibitors in Cancer Development and Therapy.The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat.HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.Immune effectors required for the therapeutic activity of vorinostat.An autophagy-dependent anticancer immune response determines the efficacy of melanoma chemotherapy.Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy.Small molecule drugs with immunomodulatory effects in cancer.Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest.Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden.Assessment of HDACi-Induced Cytotoxicity.Manipulation of B-cell responses with histone deacetylase inhibitors.HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.Control of B-cell lymphoma by therapeutic vaccination and acquisition of immune resistance is independent of direct tumour IFN-gamma signalling.The double-edged sword of IFN-γ-dependent immune-based therapies.
P2860
Q26745930-93E74208-4904-4998-ACD2-461BFD1BB22AQ26853102-69B1F3AD-C627-4BBF-BFA7-4728973D575FQ28073778-E0AB05B2-6F31-4E6F-AF6A-22988ABAE990Q28076473-4A87A40A-10E1-4B62-873B-83183E141A08Q33437948-E0377812-9E82-4327-9AFA-50E82F6B06ECQ33776397-090BA37A-1FC3-472F-BFB5-36635E929F38Q34048020-E747B61A-059B-4912-8CB6-42EE6DB8FB9DQ35048054-50EC141C-87D0-4FBF-A76E-7ED175D5C697Q35067983-92C5B124-3DAD-4E4B-B98E-EE24B46843FAQ36086345-EA12D427-68A0-4116-B8B5-36E0093B3FD5Q36301061-03F629E6-B815-48D4-B49E-B001AD9D54F0Q36517161-0CA676C3-18ED-4F9D-971F-216F0662E2C4Q36846723-BAAA205E-9F6F-4990-935D-ABA041CB1E64Q37477372-1D06618F-80EC-474A-83A0-98532C905BF0Q37565233-D85908FD-D5EE-40B4-8E63-99B46EA60640Q37669168-3971EA07-96B8-4233-8502-A1E0AD64C37DQ38240733-A34B2F0E-FD20-45CF-9AC5-841D070DFCB3Q38400818-0443BDC9-BA93-437E-85FF-4DA7341B4A7DQ38431356-664B87A7-5163-47CC-BDF1-05EDE2EE4CE5Q38710509-6C488720-28E0-4BFA-8DC4-1B1C96E81D8FQ38779204-455E18E5-AB2E-4CAC-86A9-D96F8D21BE66Q38817005-8DE0C199-904D-4330-B91F-686CF0F1EC11Q38910971-9D3584BA-ECA0-41CD-BCBE-54E103FBB8ECQ38936705-19FA350A-C359-41EA-B58C-D154575F1AB1Q38947405-8AACDA88-129E-4E49-9DEF-8468589E3B5DQ40416435-F7856EA6-CA91-456A-8425-B4BCF0B8B088Q41739174-A45B46C3-E2B3-4691-9A6E-D44F316F0705Q41871572-AB5F8173-1DDA-4CA0-969A-FB8A115AA13BQ43104031-8F501440-97D7-40B6-BE05-A80C9A0F58DAQ43179865-7599A30E-DC2F-4961-A9EB-DFFEC8941DDAQ45814047-222B9C23-3C34-423D-A62F-D3C0039B66DBQ46316392-8FB612D8-E748-4A8C-B1A6-E6F00B2C0399Q47370837-3006CB71-28FE-44C3-AF11-687F1701B4D6Q50196119-004E3916-6BC6-4D56-90CE-AA52626D43C2Q50738767-8FD0F61C-7EF3-4462-AFD9-B53C08CA29A4Q50785408-3790983A-CDB4-4E89-93FC-C4BB36B3836BQ52722728-1AE20AE2-F09C-4AF8-8B8A-12A52D27B95FQ53308070-4A72BEB4-F5DD-42F7-88B6-36DF19F9CC47Q54059543-07B74FC9-B955-4B82-99D3-3F087625BD75
P2860
An intact immune system is required for the anticancer activities of histone deacetylase inhibitors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
An intact immune system is req ...... istone deacetylase inhibitors.
@en
An intact immune system is req ...... istone deacetylase inhibitors.
@nl
type
label
An intact immune system is req ...... istone deacetylase inhibitors.
@en
An intact immune system is req ...... istone deacetylase inhibitors.
@nl
prefLabel
An intact immune system is req ...... istone deacetylase inhibitors.
@en
An intact immune system is req ...... istone deacetylase inhibitors.
@nl
P2093
P50
P1433
P1476
An intact immune system is req ...... istone deacetylase inhibitors.
@en
P2093
Ailsa J Christiansen
Alison C West
Leonie A Cluse
P304
P356
10.1158/0008-5472.CAN-13-0890
P407
P577
2013-10-24T00:00:00Z